COL11A1 dysregulation across cancer types is particularly striking, including colorectal, ovarian, breast, head and neck, lung, and brain cancers.[31] This result indicates that COL11A1 may serve as a remarkable biomarker for various types of cancers and as a target for cancer therapy. This evidence concerns the gene COL11A1 and brain cancer.